The DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index.
Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid
Abstract
The preclinical pharmacology of the alpha4beta2 nicotinic acetylcholine receptor (nAChR) partial agonist varenicline, a novel smoking cessation agent is described. Varenicline binds with subnanomolar affinity only to alpha4beta2 nAChRs and in vitro functional patch clamp studies in HEK cells expressing nAChRs show that varenicline is a partial agonist with 45% of nicotine's maximal efficacy at alpha4beta2 nAChRs. In neurochemical models varenicline has significantly lower (40-60%) efficacy than nicotine in stimulating [(3)H]-dopamine release from rat brain slices in vitro and in increasing dopamine release from rat nucleus accumbens in vivo, while it is more potent than nicotine. In addition, when combined with nicotine, varenicline effectively attenuates the nicotine-induced dopamine release to the level of the effect of varenicline alone, consistent with partial agonism. Finally, varenicline reduces nicotine self-administration in rats and supports lower self-administration break points than nicotine. These data suggest that varenicline can reproduce to some extent the subjective effects of smoking by partially activating alpha4beta2 nAChRs, while preventing full activation of these receptors by nicotine. Based on these findings, varenicline was advanced into clinical development and recently shown to be an effective and safe aid for smoking cessation treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“neither patch (Jorenby et al., 1995) nor varenicline are reinforcing (Rollema et al., 2007).”
From It is not “either/or”: Activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood (2008) · cites this paper as Rollema et al., 2007
In the citing paper
“Varenicline, the most effective medication for smoking cessation currently available (Chantix; Pfizer), is a potent partial agonist for a4b2 nAChRs, as well as a weak partial agonist at a3b4 nAChRs and a full agonist at a7 nAChRs (Coe et al, 2005; Rollema et al, 2007).”
From Divergent Functional Effects of Sazetidine-A and Varenicline During Nicotine Withdrawal (2013) · cites this paper as Rollema et al, 2007
In the citing paper
“Varenicline, the most effective medication for smoking cessation currently available (Chantix; Pfizer), is a potent partial agonist for a4b2 nAChRs, as well as a weak partial agonist at a3b4 nAChRs and a full agonist at a7 nAChRs (Coe et al, 2005; Rollema et al, 2007).”
From Divergent Functional Effects of Sazetidine-A and Varenicline During Nicotine Withdrawal (2013) · cites this paper as Rollema et al, 2007
In the citing paper
“Varenicline, the most effective medication for smoking cessation currently available (Chantix; Pfizer), is a potent partial agonist for a4b2 nAChRs, as well as a weak partial agonist at a3b4 nAChRs and a full agonist at a7 nAChRs (Coe et al, 2005; Rollema et al, 2007).”
From Divergent Functional Effects of Sazetidine-A and Varenicline During Nicotine Withdrawal (2013) · cites this paper as Rollema et al, 2007
In the citing paper
“Varenicline (Chantix; Pfizer, Groton, CT) is a potent partial agonist at ␣42 nAChRs, with 40 to 60% of the agonist efficacy of nicotine (Rollema et al., 2007), and it is a less potent partial agonist at ␣34 and a full agonist at ␣7 nAChRs (Mihalak et al., 2006;Rollema et al., 2007Rollema et al., , 2009b)).”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Rollema et al., 2007
In the citing paper
“Varenicline (Chantix; Pfizer, Groton, CT) is a potent partial agonist at ␣42 nAChRs, with 40 to 60% of the agonist efficacy of nicotine (Rollema et al., 2007), and it is a less potent partial agonist at ␣34 and a full agonist at ␣7 nAChRs (Mihalak et al., 2006;Rollema et al., 2007Rollema et al., , 2009b)).”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Rollema et al., 2007
In the citing paper
“Although the K i values for sazetidine-A and varenicline at ␣42 nAChRs are very similar (0.4 and 0.2 nM, respectively) (Xiao et al., 2006;Rollema et al., 2007)”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Rollema et al., 2007
In the citing paper
“the high-affinity ␣42 partial agonist varenicline also has moderate affinity for other nAChRs and acts as a partial agonist at ␣34 and a full agonist at ␣7 nAChRs (Mihalak et al., 2006;Rollema et al., 2007).”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Rollema et al., 2007
In the citing paper
“Although varenicline, like cytisine, is a potent and selective ␣42 partial agonist (Rollema et al., 2007)”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Rollema et al., 2007
In the citing paper
“Varenicline has at least 100-fold higher affinity for α4β2 than for other subtypes, is a 45% agonist as compared with nicotine and can potently desensitize α4β2 nicotinic acetylcholine receptors with an IC50 value of 6 nM for inhibiting nicotine-evoked currents (Rollema et al., 2007).”
From Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect (2009) · cites this paper as Rollema et al., 2007
In the citing paper
“The fact that low doses of varenicline (i.e. 0.25 mg/kg in C57BL/6J mice and 0.178 mg/kg in CD-1 mice) have significant effects in both experiments is consistent with varenicline’s high in vitro binding affinity (Ki = 0.15 nM) and inactivating potency (IC50 = 6 nM) at α4β2 nicotinic acetylcholine receptors, as well as with its potent activity in in vivo models, such as increasing mesolimbic”
From Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect (2009) · cites this paper as Rollema et al., 2007
In the citing paper
“Varenicline has at least 100-fold higher affinity for α4β2 than for other subtypes, is a 45% agonist as compared with nicotine and can potently desensitize α4β2 nicotinic acetylcholine receptors with an IC50 value of 6 nM for inhibiting nicotine-evoked currents (Rollema et al., 2007).”
From Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect (2009) · cites this paper as Rollema et al., 2007
In the citing paper
“Varenicline has at least 100-fold higher affinity for α4β2 than for other subtypes, is a 45% agonist as compared with nicotine and can potently desensitize α4β2 nicotinic acetylcholine receptors with an IC50 value of 6 nM for inhibiting nicotine-evoked currents (Rollema et al., 2007).”
From Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect (2009) · cites this paper as Rollema et al., 2007
Citations
Cites
Mortality in relation to smoking: 40 years' observations on male British doctors
Doll, R., Peto, R., Wheatley, K., Gray, R., & Sutherland, I. (1994) · BMJ · doi:10.1136/bmj.309.6959.901 · Cited by 5,932
Neural systems of reinforcement for drug addiction: from actions to habits to compulsion
Everitt, B. J., & Robbins, T. W. (2005) · Nature Neuroscience · doi:10.1038/nn1579 · Cited by 3,785
Mortality in relation to smoking: 50 years' observations on male British doctors
Doll, R., Peto, R., Boreham, J., & Sutherland, I. (2004) · BMJ · doi:10.1136/bmj.38142.554479.ae · Cited by 2,920 · cited 1×
“Department of Health and Human Services, 2004; Doll et al., 2004 ).”
BackgroundThe Health Consequences of Smoking: A Report of the Surgeon General
Office on Smoking (2004) · Cited by 2,414
Charbonneau, D. H. (2005) · Europe PMC (PubMed Central) · Cited by 2,041
Picciotto, M. R., Zoli, M., Rimondini, R., Léna, C., Marubio, L. M., Pich, E. M., Fuxe, K., & Changeux, J.-P. (1998) · Nature · doi:10.1038/34413 · Cited by 1,320
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
Pontieri, F. E., Tanda, G., Orzi, F., & Chiara, G. D. (1996) · Nature · doi:10.1038/382255a0 · Cited by 1,073
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930
Self-citation
Flagged first, then by citations
2 of the 44 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Benowitz, N. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0809890 · Cited by 1,508
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930
Self-citationNatural product and natural product derived drugs in clinical trials
Butler, M. S., Robertson, A. A. B., & Cooper, M. A. (2014) · Natural Product Reports · doi:10.1039/c4np00064a · Cited by 619
PICCIOTTO, M., ADDY, N., MINEUR, Y., & BRUNZELL, D. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.12.005 · Cited by 460
Sofouglu, M., Herman, A. I., Robinson, C. D., & Waters, A. J. (2014) · Lincoln (University of Nebraska) · Cited by 417
Rollema, H., Coe, J. W., Chambers, L. K., Hurst, R. S., Stahl, S. M., & Williams, K. E. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.05.003 · Cited by 400
Self-citation2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment
Barua, R. S., Rigotti, N. A., Benowitz, N. L., Cummings, K. M., Jazayeri, M., Morris, P. B., Ratchford, E. V., Sarna, L., Stecker, E. C., & Wiggins, B. S. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.10.027 · Cited by 391
Steensland, P., Simms, J. A., Holgate, J. Y., Richards, J. K., & Bartlett, S. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705368104 · Cited by 368
Aubin, H.-J., Bobak, A., Britton, J. R., Oncken, C., Billing, C. B., Gong, J., Williams, K. E., & Reeves, K. R. (2008) · Thorax · doi:10.1136/thx.2007.090647 · Cited by 344
Self-citationRemoving Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models
Markou, A., Chiamulera, C., Geyer, M. A., Tricklebank, M., & Steckler, T. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.173 · Cited by 328
Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis
Mineur, Y. S., & Picciotto, M. R. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.09.004 · Cited by 285
The Dynamics of DNA Methylation in Schizophrenia and Related Psychiatric Disorders
Grayson, D. R., & Guidotti, A. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.125 · Cited by 280
Howell, L. L., & Cunningham, K. A. (2014) · Pharmacological Reviews · doi:10.1124/pr.114.009514 · Cited by 262
Leone, F. T., Zhang, Y., Evers‐Casey, S., Evins, A. E., Eakin, M. N., Fathi, J. T., Fennig, K., Folan, P. A., Galiatsatos, P., Gogineni, H. P., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202005-1982st · Cited by 267
Levin, F. R., Mariani, J. J., Brooks, D. J., Pavlicova, M., Cheng, W., & Nunes, E. V. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.12.010 · Cited by 232
Smoking, quitting, and psychiatric disease: A review
Aubin, H., Rollema, H., Svensson, T. H., & Winterer, G. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.06.007 · Cited by 241
Self-citationSmoking and diabetes: dangerous liaisons and confusing relationships
Campagna, D., Alamo, A., Pino, A. D., Russo, C., Calogero, A. E., Purrello, F., & Polosa, R. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0482-2 · Cited by 246
Gotti, C., Guiducci, S., Tedesco, V., Corbioli, S., Zanetti, L., Moretti, M., Zanardi, A., Rimondini, R., Mugnaini, M., Clementi, F., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5095-09.2010 · Cited by 226
Neuronal nicotinic receptors: A perspective on two decades of drug discovery research
Arneric, S. P., Holladay, M., & Williams, M. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.033 · Cited by 208
West, R., Baker, C. L., Cappelleri, J. C., & Bushmakin, A. G. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1041-3 · Cited by 203
α6β2* and α4β2* Nicotinic Acetylcholine Receptors As Drug Targets for Parkinson’s Disease
Quik, M., & Wonnacott, S. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003269 · Cited by 201
Effects of Nicotine in Experimental Animals and Humans: An Update on Addictive Properties
Foll, B. L., & Goldberg, S. R. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-69248-5_12 · Cited by 200
The predictive validity of the rat self-administration model for abuse liability
O’Connor, E. C., Chapman, K. L., Butler, P., & Mead, A. N. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.012 · Cited by 199
Nakamura, M., Oshima, A., Fujimoto, Y., Maruyama, N., Ishibashi, T., & Reeves, K. R. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.06.012 · Cited by 185
A double-blind study evaluating the long-term safety of varenicline for smoking cessation
Williams, K. E., Reeves, K. R., Billing, C. B., Pennington, A. M., & Gong, J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x182185 · Cited by 184
Self-citationRollema, H., Shrikhande, A., Ward, K., Tingley III, F., Coe, J., O'Neill, B., Tseng, E., Wang, E., Mather, R., Hurst, R., et al. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00682.x · Cited by 162
Self-citationCardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers
Benowitz, N. L., Pipe, A., West, R., Hays, J. T., Tonstad, S., McRae, T. D., Lawrence, D., Aubin, L. S., & Anthenelli, R. M. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.0397 · Cited by 167
Picciotto, M. R., Lewis, A. S., van Schalkwyk, G. I., & Mineur, Y. S. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.12.028 · Cited by 157
Development of pharmacotherapies for drug addiction: a Rosetta stone approach
Koob, G. F., Kenneth Lloyd, G., & Mason, B. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2828 · Cited by 154
Hong, L. E. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.83 · Cited by 150
Translational research in medication development for nicotine dependence
Lerman, C. E., LeSage, M. G., Perkins, K. A., O’Malley, S. S., Siegel, S. J., Benowitz, N. L., & Corrigall, W. A. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2361 · Cited by 150
Tonstad, S., Davies, S., Flammer, M., Russ, C., & Hughes, J. (2010) · Drug Safety · doi:10.2165/11319180-000000000-00000 · Cited by 142
Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice
Aubin, H., Luquiens, A., & Berlin, I. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12116 · Cited by 138
Anthenelli, R. M., Morris, C. D., Ramey, T. S., Dubrava, S., Tsilkos, K., Russ, C., & Yunis, C. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-6-201309170-00005 · Cited by 143
Treatment of nicotine addiction: present therapeutic options and pipeline developments
Polosa, R., & Benowitz, N. L. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.12.008 · Cited by 135
Nicotine Dependence Pharmacogenetics: Role of Genetic Variation in Nicotine-Metabolizing Enzymes
Ray, R., Tyndale, R. F., & Lerman, C. E. (2009) · Journal of Neurogenetics · doi:10.1080/01677060802572887 · Cited by 135
Tsai, S.-T., Cho, H., Cheng, H., Kim, C.-H., Hsueh, K.-C., Billing, C. B., & Williams, K. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.06.011 · Cited by 134
Self-citationFowler, C. D., Arends, M. A., & Kenny, P. J. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32830c360e · Cited by 131
Sutherland, M. T., Carroll, A. J., Salmeron, B. J., Ross, T. J., Hong, L. E., & Stein, E. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.01.035 · Cited by 134
Czoty, P. W., Stoops, W. W., & Rush, C. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011668 · Cited by 131
Varenicline: A first-line treatment option for smoking cessation
Garrison, G. D., & Dugan, S. E. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.03.021 · Cited by 140
Update on Pharmacologic Options for Smoking Cessation Treatment
Nides, M. A. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.01.016 · Cited by 130
Neurobiological Mechanisms of Nicotine Reward and Aversion
Wills, L. P., Ables, J. L., Braunscheidel, K. M., Caligiuri, S. P. B., Elayouby, K. S., Fillinger, C., Ishikawa, M., Moen, J. K., & Kenny, P. J. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000299 · Cited by 134
Loughead, J., Ray, R., Wileyto, E. P., Ruparel, K., Sanborn, P. M., Siegel, S. J., Gur, R. C., & Lerman, C. E. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.01.016 · Cited by 123
Making a bad thing worse: adverse effects of stress on drug addiction
Cleck, J. N., & Blendy, J. A. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33946 · Cited by 122
Existing and future drugs for the treatment of the dark side of addiction
Koob, G. F., & Mason, B. J. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103143 · Cited by 121
A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Varenicline for Smoking Cessation
Faessel, H. M., Obach, R. S., Rollema, H., Ravva, P., Williams, K. E., & Burstein, A. H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11537850-000000000-00000 · Cited by 127
Self-citationA randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3
Zesiewicz, T. A., Greenstein, P. E., Sullivan, K. L., Wecker, L., Miller, A., Jahan, I., Chen, R., & Perlman, S. (2012) · Neurology · doi:10.1212/wnl.0b013e318247cc7a · Cited by 119
O’Connor, E. C., Parker, D., Rollema, H., & Mead, A. N. (2010) · Psychopharmacology · doi:10.1007/s00213-009-1739-5 · Cited by 118
Self-citationRollema, H., Hajós, M., Seymour, P. A., Kozak, R., Majchrzak, M. J., Guanowsky, V., Horner, W. E., Chapin, D. S., Hoffmann, W. E., Johnson, D. E., et al. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.033 · Cited by 118
Self-citationShim, J.-C., Jung, D.-U., Jung, S. S., Seo, Y.-S., Cho, D.-M., Lee, J.-H., Lee, S.-W., Kong, B.-G., Kang, J.-W., Oh, M., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.238 · Cited by 112
Bito‐Onon, J. J., Simms, J. A., Chatterjee, S., Holgate, J. Y., & Bartlett, S. E. (2011) · Addiction Biology · doi:10.1111/j.1369-1600.2010.00309.x · Cited by 114
Ericson, M., Löf, E., Stomberg, R., & Söderpalm, B. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.147058 · Cited by 109
Varenicline for Treatment of Alcohol Dependence: A Randomized, Placebo‐Controlled Trial
de Bejczy, A., Löf, E., Walther, L., Guterstam, J., Hammarberg, A., Asanovska, G., Franck, J., Isaksson, A., & Söderpalm, B. (2015) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12854 · Cited by 107
Adeluyi, A., Guerin, L. N., Fisher, M. L., Galloway, A. L., Cole, R. D., Chan, S. S. L., Wyatt, M. D., Davis, S. W., Freeman, L. R., Ortinski, P. I., et al. (2019) · Science Advances · doi:10.1126/sciadv.aax7031 · Cited by 109
Chatterjee, S., Steensland, P., Simms, J. A., Holgate, J. Y., Coe, J. W., Hurst, R. S., Shaffer, C. L., Lowe, J. A., III, Rollema, H., & Bartlett, S. E. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.191 · Cited by 103
Self-citationFakhfouri, G., Rahimian, R., Dyhrfjeld‐Johnsen, J., Zirak, M. R., & Beaulieu, J. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.015487 · Cited by 105
Hendrickson, L. M., Zhao-Shea, R., Pang, X.-Y., Gardner, P. D., & Tapper, A. R. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.2601-10.2010 · Cited by 101
Kamens, H. M., Andersen, J., & Picciotto, M. R. (2010) · Psychopharmacology · doi:10.1007/s00213-009-1759-1 · Cited by 101
Wouda, J. A., Riga, D., de Vries, W., Stegeman, M., van Mourik, Y., Schetters, D., Schoffelmeer, A. N. M., Pattij, T., & Vries, T. J. D. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2213-8 · Cited by 99
Chatterjee, S., & Bartlett, S. E. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710790966597 · Cited by 100
Grady, S. R., Drenan, R. M., Breining, S. R., Yohannes, D., Wageman, C. R., Fedorov, N. B., McKinney, S., Whiteaker, P., Bencherif, M., Lester, H. A., et al. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.01.013 · Cited by 98
From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists
Higgins, G. A., Sellers, E. M., & Fletcher, P. J. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.08.001 · Cited by 100
Influence of Neuronal Nicotinic Receptors over Nicotine Addiction and Withdrawal
De Biasi, M., & Salas, R. (2008) · Experimental Biology and Medicine · doi:10.3181/0712-mr-355 · Cited by 95
Brunzell, D. H., Boschen, K. E., Hendrick, E. S., Beardsley, P. M., & McIntosh, J. M. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.171 · Cited by 95
“…, 2007; Drenan et al , 2008; Pons et al , 2008), making these receptors an attractive therapeutic target for tobacco cessation (Gonzales et al , 2006; Rollema et al , 2007). β 2*nAChRs, however, have a ubiquitous expression pattern and contribute more generally to motivation, mood, and cognition…”
Using conditioned place preference to identify relapse prevention medications
Napier, T. C., Herrold, A. A., & de Wit, H. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.05.002 · Cited by 93
Cognitive Enhancers (Nootropics). Part 1: Drugs Interacting with Receptors
Froestl, W., Muhs, A., & Pfeifer, A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121186 · Cited by 94
Discovery and development of varenicline for smoking cessation
Jordan, C. J., & Xi, Z. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1458090 · Cited by 103
Treating Tobacco Dependence in Women
Schnoll, R. A., Patterson, F., & Lerman, C. E. (2007) · Journal of Women s Health · doi:10.1089/jwh.2006.0281 · Cited by 94
Rezvani, A. H., Slade, S., Wells, C., Petro, A., Lumeng, L., Li, T.-K., Xiao, Y., Brown, M. L., Paige, M. A., McDowell, B. E., et al. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1878-8 · Cited by 88
Turner, J. R., Castellano, L. M., & Blendy, J. A. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166280 · Cited by 88
Rollema, H., Guanowsky, V., Mineur, Y. S., Shrikhande, A., Coe, J. W., Seymour, P. A., & Picciotto, M. R. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.01.002 · Cited by 87
Self-citationStopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial
Fagerström, K., Gilljam, H., Metcalfe, M., Tonstad, S., & Messig, M. (2010) · BMJ · doi:10.1136/bmj.c6549 · Cited by 87
Varenicline Augmentation in Depressed Smokers: An 8-Week, Open-Label Study
Philip, N. S., Carpenter, L. L., Tyrka, A. R., Whiteley, L. B., & Price, L. H. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04441 · Cited by 86
Pharmacotherapy for amphetamine dependence: A systematic review.
Lee, N., Jenner, L., Harney, A., & Cameron, J. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.06.038 · Cited by 70
Feng, B., Obach, R., Burstein, A., Clark, D., de Morais, S., & Faessel, H. M. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100405 · Cited by 85
Efficacy and Safety of Varenicline for Smoking Cessation
Hays, J. T., Ebbert, J. O., & Sood, A. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.01.017 · Cited by 84
Keever, K. R., Yakubenko, V. P., & Hoover, D. B. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106758 · Cited by 82
Nicotinic acetylcholine receptors: an overview on drug discovery
D’hoedt, D., & Bertrand, D. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902841045 · Cited by 79
Role of the Glutamatergic System in Nicotine Dependence
Liechti, M. E., & Markou, A. (2008) · CNS Drugs · doi:10.2165/00023210-200822090-00001 · Cited by 79
Smith, R. C., Amiaz, R., Si, T., Maayan, L. A., Jin, H., Boules, S., Sershen, H. W., Li, C., Ren, J., Liu, Y., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0143490 · Cited by 83
Comparison of the reinforcing properties of nicotine and cigarette smoke extract in rats
Costello, M. R., Reynaga, D. D., Mojica, C. Y., Zaveri, N. T., Belluzzi, J. D., & Leslie, F. M. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.31 · Cited by 78
LeSage, M. G., Shelley, D., Ross, J. T., Carroll, F. I., & Corrigall, W. A. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.08.024 · Cited by 79
Toll, L., Zaveri, N. T., Polgar, W. E., Jiang, F., Khroyan, T. V., Zhou, W., Xie, X., Stauber, G. B., Costello, M. R., & Leslie, F. M. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.322 · Cited by 80
Varenicline in the treatment of tobacco dependence
Fagerström, K. O. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s927 · Cited by 78
Functional alterations by a subgroup of neonicotinoid pesticides in human dopaminergic neurons
Loser, D., Hinojosa, M. G., Blum, J. H., Schaefer, J., Brüll, M., Johansson, Y., Suciu, I., Grillberger, K., Danker, T., Möller, C., et al. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03031-1 · Cited by 77
Recognising Nicotine: The Neurobiological Basis of Nicotine Discrimination
Smith, J. W., & Stolerman, I. P. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-69248-5_11 · Cited by 75
Huang, L. Z., Campos, C., Ly, J., Carroll, F. I., & Quik, M. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.12.032 · Cited by 76
Jimenez-Ruiz, C. A., Berlin, I., & Hering, T. (2009) · Drugs · doi:10.2165/00003495-200969100-00003 · Cited by 76
McCallum, S. E., Cowe, M. A., Lewis, S. W., & Glick, S. D. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.04.015 · Cited by 76
Varenicline Is a Potent Agonist of the Human 5-Hydroxytryptamine3 Receptor
Lummis, S. C. R., Thompson, A. J., Bencherif, M., & Lester, H. A. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.185306 · Cited by 71
Feduccia, A. A., Simms, J. A., Mill, D., Yi, H. Y., & Bartlett, S. E. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12690 · Cited by 70
Faessel, H. M., Ravva, P., & Williams, K. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.01.003 · Cited by 71
Self-citationCellular, molecular, and genetic substrates underlying the impact of nicotine on learning
Gould, T. J., & Leach, P. T. (2013) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.08.004 · Cited by 72
Flavors Enhance Nicotine Vapor Self-administration in Male Mice
Cooper, S. Y., Akers, A. T., & Henderson, B. J. (2020) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntaa165 · Cited by 68
Papke, R. L., Wecker, L., & Stitzel, J. A. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.164566 · Cited by 66
Portugal, G. S., Kenney, J. W., & Gould, T. J. (2008) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2007.05.002 · Cited by 66
Levin, E. D., Rezvani, A. H., Xiao, Y., Slade, S., Cauley, M., Wells, C., Hampton, D., Petro, A., Rose, J. E., Brown, M. L., et al. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.162073 · Cited by 65
Tonstad, S., Arons, C., Rollema, H., Berlin, I., Hájek, P., Fagerström, K. O., Els, C., McRae, T. D., & Russ, C. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1729708 · Cited by 66
Self-citationTreating Tobacco Dependence in a Medical Setting
Hurt, R. D., Ebbert, J. O., Hays, J. T., & McFadden, D. D. (2009) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20031 · Cited by 66
Metadata
- Authors
- Rollema, H., Chambers, L. K., Coe, J. W., Glowa, J., Hurst, R. S., Lebel, L. A., Lu, Y., Mansbach, R. S., Mather, R. J., Rovetti, C. C., Sands, S. B., Schaeffer, E., Schulz, D. W., Tingley, F. D., & Williams, K. E.
- Affiliations
- Pfizer (United States) (US)
- Corresponding author
- Rollema, H.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2007-03
- Volume
- 52
- Issue
- 3
- Pages
- 985-994
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2101520329
- Cited by
- 533
- References
- 44
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 9 · 2023: 13 · 2022: 16 · 2021: 19 · 2020: 27 · 2019: 25 · 2018: 27 · 2017: 20 · 2016: 27 · 2015: 37 · 2014: 34 · 2013: 34 · 2012: 41
- FWCI
- 13.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuropharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- varenicline, α4β2 nicotinic acetylcholine receptor, partial agonism, smoking cessation, nicotine self-administration, dopamine release, nucleus accumbens, receptor binding affinity
- MeSH terms
- Varenicline, Animals, Behavior, Animal, Benzazepines, Brain, Cell Line, Transformed, Dopamine, Dose-Response Relationship, Drug, Drug Administration Schedule, Humans, Male, Membrane Potentials, Nicotine, Protein Binding, Quinoxalines, Self Administration, Transfection, Smoking Cessation, Rats, Sprague-Dawley, Patch-Clamp Techniques, Nicotinic Agonists, Rats, Long-Evans, Rats, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
